Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Ritchie

Showing results (11-20 of 91) with videos related to

Pageof 10
Sort By:
Leukemia Research|September 4, 2014
The passive-aggressive relationship between CLL-B cells and T cell immunityJoanne E Davis, David S Ritchie
Haematologica|October 3, 2019
Pediatric aplastic anemia treatment patterns and responses; power in the numbersLucy C Fox, David S Ritchie
Current Opinion in Immunology|March 18, 2014
Editorial overview: Tumour immunology: New frontiers in cancer immunotherapyPhillip K Darcy, David S Ritchie
Oncoimmunology|June 28, 2012
Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?Andy Hsu, David S Ritchie, Paul Neeson
Lancet (London, England)|July 31, 2002
Tumour antigens on tapFranca Ronchese, Simon Prasad, David S Ritchie
Leukemia & Lymphoma|September 27, 2013
Hodgkin lymphoma, allogeneic transplant and the graft-versus-tumor effect: size does matterAndrew B M Lim, David S Ritchie
European Journal of Haematology|September 13, 2002
Aplastic anemia as a late complication of thymoma in remissionDavid S Ritchie, Craig Underhill, Andrew P Grigg
The New England Journal of Medicine|June 26, 2024
Response and Resistance to Menin Inhibitor in <i>UBTF</i>-Tandem Duplication AMLIng Soo Tiong, David S Ritchie, Piers Blombery
Leukemia Research|August 27, 2016
CIK immunotherapy in refractory hematologic malignanciesEric Wong, David S Ritchie, Joanne E Davis
Leukemia & Lymphoma|May 24, 2011
Strategies to optimize collection of hematopoietic stem cells in patients with mantle cell lymphoma receiving hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate (Hyper-CVAD) chemotherapyKirsten E Herbert, David S Ritchie, John F Seymour
Pageof 10

Showing results (11-20 of 91) with videos related to

Sort By:
Pageof 10
Leukemia Research|September 4, 2014
The passive-aggressive relationship between CLL-B cells and T cell immunityJoanne E Davis, David S Ritchie
Haematologica|October 3, 2019
Pediatric aplastic anemia treatment patterns and responses; power in the numbersLucy C Fox, David S Ritchie
Current Opinion in Immunology|March 18, 2014
Editorial overview: Tumour immunology: New frontiers in cancer immunotherapyPhillip K Darcy, David S Ritchie
Oncoimmunology|June 28, 2012
Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?Andy Hsu, David S Ritchie, Paul Neeson
Lancet (London, England)|July 31, 2002
Tumour antigens on tapFranca Ronchese, Simon Prasad, David S Ritchie
Leukemia & Lymphoma|September 27, 2013
Hodgkin lymphoma, allogeneic transplant and the graft-versus-tumor effect: size does matterAndrew B M Lim, David S Ritchie
European Journal of Haematology|September 13, 2002
Aplastic anemia as a late complication of thymoma in remissionDavid S Ritchie, Craig Underhill, Andrew P Grigg
The New England Journal of Medicine|June 26, 2024
Response and Resistance to Menin Inhibitor in <i>UBTF</i>-Tandem Duplication AMLIng Soo Tiong, David S Ritchie, Piers Blombery
Leukemia Research|August 27, 2016
CIK immunotherapy in refractory hematologic malignanciesEric Wong, David S Ritchie, Joanne E Davis
Leukemia & Lymphoma|May 24, 2011
Strategies to optimize collection of hematopoietic stem cells in patients with mantle cell lymphoma receiving hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate (Hyper-CVAD) chemotherapyKirsten E Herbert, David S Ritchie, John F Seymour
Pageof 10